These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 30268448)

  • 61. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
    Spigel DR; Chaft JE; Gettinger S; Chao BH; Dirix L; Schmid P; Chow LQM; Hicks RJ; Leon L; Fredrickson J; Kowanetz M; Sandler A; Funke R; Rizvi NA
    J Thorac Oncol; 2018 Nov; 13(11):1733-1742. PubMed ID: 29775807
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
    Mitchell KG; Negrao MV; Parra ER; Li J; Zhang J; Dejima H; Vaporciyan AA; Swisher SG; Weissferdt A; Antonoff MB; Cascone T; Roarty E; Wistuba II; Heymach JV; Gibbons DL; Zhang J; Sepesi B
    Ann Thorac Surg; 2020 Feb; 109(2):358-366. PubMed ID: 31550464
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Yoh K; Matsumoto S; Furuya N; Nishino K; Miyamoto S; Oizumi S; Okamoto N; Itani H; Kuyama S; Nakamura A; Nishi K; Fukuda I; Tsuta K; Hayashi Y; Motoi N; Ishii G; Goto K
    Lung Cancer; 2021 Sep; 159():128-134. PubMed ID: 34333203
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer.
    Li L; Xu C; Wang W; Zhang Q
    Clin Respir J; 2024 May; 18(5):e13763. PubMed ID: 38717297
    [TBL] [Abstract][Full Text] [Related]  

  • 65. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
    Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
    Dudnik E; Moskovitz M; Daher S; Shamai S; Hanovich E; Grubstein A; Shochat T; Wollner M; Bar J; Merimsky O; Zer A; Goldstein DA; Hammerman A; Cyjon A; Shechtman Y; Abu-Amna M; Flex D; Roisman LC; Peled N;
    Lung Cancer; 2018 Dec; 126():217-223. PubMed ID: 29254746
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
    Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies.
    Shukuya T; Mori K; Amann JM; Bertino EM; Otterson GA; Shields PG; Morita S; Carbone DP
    J Thorac Oncol; 2016 Nov; 11(11):1927-1939. PubMed ID: 27496650
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Frigola J; Navarro A; Carbonell C; Callejo A; Iranzo P; Cedrés S; Martinez-Marti A; Pardo N; Saoudi-Gonzalez N; Martinez D; Jimenez J; Sansano I; Mancuso FM; Nuciforo P; Montuenga LM; Sánchez-Cespedes M; Prat A; Vivancos A; Felip E; Amat R
    Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
    Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.
    Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J
    JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
    Zhang Y; Song L; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Wang Z; Xia Q; Jiang W; Xu Q; Yang N
    BMC Cancer; 2022 Sep; 22(1):952. PubMed ID: 36064386
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis.
    Abdel-Rahman O
    Crit Rev Oncol Hematol; 2016 May; 101():75-85. PubMed ID: 26969107
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study.
    Bjørnhart B; Hansen KH; Jørgensen TL; Herrstedt J; Schytte T
    Acta Oncol; 2019 Jul; 58(7):953-961. PubMed ID: 31081424
    [No Abstract]   [Full Text] [Related]  

  • 76. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
    He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
    Ahn BC; Pyo KH; Xin CF; Jung D; Shim HS; Lee CY; Park SY; Yoon HI; Hong MH; Cho BC; Kim HR
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1613-1623. PubMed ID: 30911841
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients.
    Chen RL; Zhou JX; Cao Y; Li SH; Li YH; Jiang M; Lu DY; Li P; Lin LZ
    Immunotherapy; 2019 Dec; 11(17):1481-1490. PubMed ID: 31713453
    [No Abstract]   [Full Text] [Related]  

  • 79. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis.
    Miyashita K; Karayama M; Inoue Y; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kono M; Matsui T; Niwa M; Koda K; Toyoshima M; Matsushima S; Matsuura S; Asada K; Fujii M; Kusagaya H; Matsuda H; Inui N; Suda T
    BMC Pulm Med; 2021 Oct; 21(1):309. PubMed ID: 34600514
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
    Meniawy TM; Lake RA; McDonnell AM; Millward MJ; Nowak AK
    Lung Cancer; 2016 Mar; 93():9-16. PubMed ID: 26898608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.